Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by cra1gBon Mar 01, 2021 9:20am

103 Views

Post# 32684177

9:20 Level 2

$0.09	3264000	101	$0.09	3405000	74
$0.085	22000	3	$0.095	1023000	15
$0.08	226000	8	$0.10	2352000	25
$0.075	393000	11	$0.105	581000	4
$0.07	1433000	48	$0.11	1348000	14
$0.065	443000	28	$0.115	501000	2
$0.06	906000	31	$0.12	1783000	14
$0.055	561000	17	$0.125	47000	4
$0.05	1716000	22	$0.13	294000	9
$0.045	932000	13	$0.135	599000	5